

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

40032

APPROVAL LETTER

ANDA 40-032

AUG 17 1999

Roxane Laboratories, Inc.
Attention: Sean Alan F.X. Reade
P.O. Box 16532
Columbus, Ohio 43216

Dear Sir:

This is in reference to your abbreviated new drug application dated November 26, 1991, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Cyclophosphamide Tablets USP, 25 mg and 50 mg.

Reference is also made to your amendments dated December 13, 1993; May 17, and July 12, 1994; January 5, and January 13, 1995; January 8, 1996; July 9, 1997; August 10, and September 3, 1998; and June 22, July 13 and July 23, 1999.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Cyclophosphamide Tablets USP, 25 mg and 50 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Cytoxan® Tablets, 25 mg and 50 mg, respectively, of Bristol Myers Squibb Co. Pharmaceutical Research Institute). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.


We request that you submit, in duplicate, any proposed advertising or promotional copy that you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print.

Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

RS



Roger L. Williams, M.D.
Deputy Center Director for
Pharmaceutical Science
Center for Drug Evaluation and Research